ALERTNESX/EDS TREATMENTS REVIEWED BY NEUROINVESTMENT
NeuroInvestment today announced the release of its June issue, which reviews novel analgesics being developed for the treatment of alertness and excessive daytime sleepiness (EDS). This category covers a broad
range of pathology, ranging from the truly devastating effects of narcolepsy,
to the widespread but modest effects of circadian rhythm disruption, due to shiftwork
changes or jet lag.